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Abstract The potent immunosuppressive drug FTY720, a
sphingosine analog, induces redistribution of lymphocytes from
circulation to secondary lymphoid tissues. FTY720 is phosphor-
ylated in vivo and functions as an agonist for four G-protein-
coupled sphingosine-1-phosphate receptors. The identity of the
kinase that phosphorylates FTY720 is still not known. Here we
report that although both sphingosine kinase type 1 (SphK1)
and type 2 (SphK2) can phosphorylate FTY720 with low e⁄-
ciency, SphK2 is much more e¡ective than SphK1. FTY720
inhibited phosphorylation of sphingosine catalyzed by SphK2
to a greater extent than it inhibits SphK1. Thus, SphK2 may
be the relevant enzyme that is responsible for in vivo phosphor-
ylation of FTY720.
, 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The novel immunosuppressant FTY720 (2-amino-2-(2-[4-
octylphenyl]ethyl)-1,3-propanediol) prevents transplant graft
rejections and inhibits a variety of experimental autoimmune
disorders, including type I diabetes mellitus [1], systemic lupus
erythematosus [2], autoimmune encephalomyelitis [3], and ar-
thritis [4]. FTY720 is even e¡ective in preventing rejection of
renal transplants in man [5,6]. FTY720 has recently received
much attention since in contrast to other immunosuppressive
agents, it acts to speci¢cally induce sequestration of lympho-
cytes without causing cytotoxicity or suppressing growth po-
tential [5]. Thus, FTY720 may provide an advantage over
current immunosuppressive therapies.
FTY720 is derived from ISP-1 (myriocin), a fungal sphin-
gosine-like metabolite used in Chinese herbal medicine [7].
Unlike ISP-1, FTY720 does not cause gastrointestinal toxicity
and does not inhibit serine palmitoyl transferase [8], the rate
limiting enzyme in de novo sphingolipid biosynthesis. It has
recently been reported that FTY720 is phosphorylated to
form a potent sphingosine-1-phosphate (S1P) analog that in-
teracts with four of the ¢ve S1P receptors and thus could
activate many signaling pathways [9,10]. Treatment with
FTY720 or its phosphorylated form results in transient lym-
phopenia due to reversible redistribution of lymphocytes from
the circulation to secondary lymphoid tissues by still not well-
de¢ned mechanisms [8^10]. The redirection of T lymphocytes
away from tissue grafts and sites of in£ammation is thought
to underlie the e¡ectiveness of FTY720 in transplantation and
autoimmunity.
As FTY720 is phosphorylated in vivo and is a sphingosine
analog, it might be expected to be phosphorylated by a sphin-
gosine kinase (SphK), the enzyme that catalyzes the formation
of S1P [11^13]. Because recombinant SphK1 catalyzed the
phosphorylation of FTY720 and the active R enantiomer of
the FTY720 analog AAL, but not the inactive S enantiomer,
it was suggested SphK1 is the kinase that converts FTY720 to
its active form [10]. However, FTY720 was phosphorylated by
SphK1 around 500-fold less e⁄ciently than sphingosine [10],
raising the possibility that SphK1 may not phosphorylate
FTY720 in vivo. We have cloned and characterized another
isoform of SphK [13]. Although it contains the ¢ve conserved
domains found in all SphKs, SphK2 is much larger than
SphK1, has a di¡erent tissue distribution and di¡erent pattern
of developmental expression, and slightly di¡erent kinetic
properties and substrate speci¢city [13] (Table 1). Whereas
SphK1 stimulates growth and survival, we recently found
that SphK2 enhanced apoptosis in diverse cell types and
also suppressed cellular proliferation [14]. The apoptotic e¡ect
of SphK2 might be due to its putative BH3 domain [14], a
motif present in the BH3-only pro-apoptotic subgroup of the
Bcl-2 family. Because of the clinical importance of FTY720
and its phosphorylated product, it is important to identify the
kinase that phosphorylates it. Here we report that SphK2
catalyzes the phosphorylation of FTY720 much more e⁄-
ciently than SphK1, suggesting that the therapeutic e⁄cacy
of FTY720 might be dependent on in vivo activity of SphK2.
2. Materials and methods
2.1. Materials
S1P was from Biomol Research Laboratory Inc. (Plymouth Meet-
ing, PA, USA). All other lipids were purchased from Avanti Polar
Lipids (Birmingham, AL, USA). FTY720 was kindly provided by Dr.
Volker Brinkmann, Novartis Pharma AG. [Q-32P]ATP (3000 Ci/mmol)
was purchased from Perkin Elmer (Boston, MA, USA). Lipofectam-
ine was from Life Technologies (Gaithersburg, MD, USA).
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2.2. Cell culture and transfection
Human embryonic kidney (HEK 293) cells (ATCC CRL-1573) cul-
tured in high glucose Dulbecco’s modi¢ed Eagle’s medium (DMEM)
containing 2 mM L-glutamine supplemented with 10% heat inacti-
vated fetal bovine serum were seeded (2U106 cells) in poly-D-lysine-
coated 100 mm dishes. After 24 h, cells were transfected for 3 h with
4 Wg of V5-His-pcDNA3.1 vector (Invitrogen), C-terminal V5-His-
tagged murine SphK1, or C-terminal V5-His-tagged murine SphK2
and 20 Wl of Lipofectamine PLUS reagent plus 30 Wl of Lipofectamine
reagent as recommended by the manufacturer. Cells were then cul-
tured for 2 days in the same DMEM medium and lysed by freeze^
thawing as described previously [12]. Proteins were measured by the
Bradford method (Bio-Rad).
2.3. SphK activity
SphK activity was measured using 10 Wg cell lysates with 50 WM
sphingosine, prepared as a complex with 4 mg/ml bovine serum albu-
min (BSA), and [Q-32P]ATP (10 WCi, 1 mM) containing MgCl2 (10
mM) in bu¡er containing 20 mM Tris (pH 7.4), 10% glycerol, 1 mM
2-mercaptoethanol, 1 mM EDTA, 5 mM sodium orthovanadate, 40
mM L-glycerophosphate, 15 mM NaF, 10 Wg/ml leupeptin, aprotinin
and soybean trypsin inhibitor, 1 mM phenylmethylsulfonyl £uoride,
and 0.5 mM 4-deoxypyridoxine in a ¢nal volume of 200 Wl, as de-
scribed previously [12], unless otherwise indicated. Phosphorylation
was also determined in the presence of 200 mM KCl, conditions in
which SphK2 activity is optimal [13]. SphK1 activity was also mea-
sured with FTY720 or sphingosine in 0.25% Triton X-100, as de-
scribed previously [12]. In preliminary experiments, phosphorylation
of FTY720 or sphingosine was found to be linear with time for at
least 60 min. Thus, phosphorylation reactions were usually carried out
for 30 min at 37‡C and less than 10% of the substrate was converted
to product. Labeled FTY720 and S1P were separated by thin layer
chromatography (TLC) on silica gel G60 with chloroform/acetone/
methanol/acetic acid/water (10:4:3:2:1, v/v) as solvent and the radio-
active spots corresponding to phosphorylated FTY720 and S1P were
quanti¢ed with a FX Molecular Imager (Bio-Rad, Hercules, CA,
USA). Background was determined in the absence of substrate. Ac-
tivity is expressed as pmol phosphorylated product formed per min
per mg protein.
Inhibition of sphingosine phosphorylation by FTY720 was exam-
ined with D-erythro-[3-3H]sphingosine (10 WM, 1 WCi) from Perkin
Elmer (Boston, MA, USA) as substrate. [3H]S1P produced was mea-
sured by a di¡erential solvent extraction procedure [15]. Brie£y, ki-
nase reactions were stopped by the addition of 1 ml methanol and 100
Wl 3 N NaOH. After adding 1 ml CHCl3 and 0.8 ml 1 N NaCl,
samples were vigorously vortexed, phases separated by centrifugation,
and an aliquot of the aqueous phase containing s 95% of the [3H]S1P
counted by liquid scintillation. Essentially all (s 95%) of the
[3H]sphingosine was recovered in the organic phase.
2.4. Western blotting
HEK 293 cells were scraped in kinase bu¡er, equal amounts of
proteins (10 Wg) separated by 10% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE), and then transblotted to ni-
trocellulose. Anti-V5 (1:5000, Life Technologies) or anti-tubulin
(1:2000, Santa Cruz Biotechnology) were used as primary antibodies
followed by anti-rabbit HRP-conjugated IgG (1:10 000, Jackson Im-
munoresearch Laboratories). Immunocomplexes were visualized by
enhanced chemiluminescence (Pierce) as described previously [14].
3. Results and discussion
3.1. Expression of SphK1 and SphK2
To examine which of the SphKs is the kinase that phos-
phorylates FTY720, C-terminal V5 epitope-tagged mSphK1
and mSphK2 were overexpressed in HEK 293 cells. These
cells were selected because they are e⁄ciently transfected
and control HEK 293 cells have low levels of SphK activity
(Fig. 1A). Forty-eight hours after transfection with SphK1,
sphingosine phosphorylating activity in cell lysates was in-
creased by more than 200-fold, whereas transfection with
SphK2 resulted in only a 20-fold increase of sphingosine phos-
phorylating activity (Fig. 1A). The relative in vitro activities
also correlated somewhat with expression of the recombinant
proteins as determined by Western blotting (Fig. 1B).
SphK1 and SphK2 expressed in HEK 293 cells can be dis-
tinguished on the basis of di¡erential activity measured when
the substrate sphingosine is added as a BSA complex in the
presence of 200 mM KCl, conditions which are optimal for
SphK2 and decrease SphK1 activity [13]. Whereas, when
sphingosine is presented to the enzymes in Triton X-100,
SphK2 activity is strongly inhibited and SphK1 activity is
increased [13] (Fig. 1A).
3.2. FTY720 is a poor substrate for SphK1
Initial kinase reactions were carried out in the presence of
Triton X-100, a detergent that stimulates SphK1 activity with
sphingosine as substrate. Although vector-transfected cells did
not signi¢cantly phosphorylate FTY720, recombinant SphK1
was able to catalyze concentration-dependent phosphorylation
of FTY70 (Fig. 2B,C). Typical Michaelis^Menten kinetics
were observed for recombinant SphK1 with either sphingosine
or FTY720 as substrate. The Km for D-erythro-sphingosine as
substrate was similar to previously reported values for SphK1
[11,12] and was not signi¢cantly di¡erent than that of
FTY720. However, Vmax for FTY720 was more than 100-
fold lower. Although FTY720 is much more water soluble
than sphingosine, similar results were obtained when
FTY720 was added as a BSA complex and there were no
signi¢cant changes in phosphorylation of FTY720 (Vmax was
Table 1
Distinct characteristics of SphK1 and SphK2
SphK1 SphK2
Conserved domains 5 5
BH3 motif None 1
Tissue expression (high) Lung, spleen Liver, heart
Developmental expression E7 E11
Localization Cytosol (V70%) Cytosol (V70%)
Cell growth Stimulated Inhibited
Apoptosis Suppressed Stimulated
Substrate speci¢city D-erythro-sphingosine D-erythro-DH-sphingosinesD-erythro-sphingosine
Inhibitors DMSa (competitive) DMSa (non-competitive)
KCl Inhibits Stimulates
Triton X-100 Stimulates Inhibits
Acidic phospholipids Stimulate Stimulate
Chromosome location 17q25.2 19q13.2
aDMS, N,N-dimethylsphingosine.
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28T 1 in BSA conditions compared to 29T 1 pmol/min/mg in
Triton X-100).
3.3. Phosphorylation of FTY720 by SphK2
Because FTY720 was phosphorylated by SphK1 at less
than 1% of the rate of sphingosine, we next examined the
ability of SphK2 to phosphorylate FTY720. In contrast to
SphK1, which has pro-survival e¡ects and can be highly over-
expressed, SphK2 overexpression is detrimental to cells [14]
and it cannot be expressed to the same level as SphK1 (Fig.
1B). Nevertheless, the sphingosine phosphorylating activity of
HEK 293 cells transiently transfected with SphK2 was mark-
edly increased compared to empty vector-transfected cells.
Although SphK2 expression at the protein level was much
lower than SphK1 (Fig. 1B) and the total sphingosine phos-
phorylating activity in SphK1 expressing cells was much
Fig. 1. Expression and enzymatic activities of SphK1 and SphK2. A: HEK 293 cells were transiently transfected with vector, V5-tagged
mSphK1, or V5-tagged mSphK2. Cell lysates were prepared and SphK activity measured with sphingosine (50 WM) added in Triton X-100
(¢lled bars) or as a BSA complex in the presence of 200 mM KCl (open bars). Data are meansTS.D. of triplicate determinations. Similar re-
sults were obtained in three independent experiments. B: In duplicate cultures, lysate proteins were resolved by SDS^PAGE and analyzed by
Western blotting with anti-V5 antibody. The blots were stripped and probed with anti-L-tubulin as a loading control.
Fig. 2. FTY720 is a poor substrate for SphK1. Phosphorylation of sphingosine (A) and FTY720 (B), added as Triton X-100 mixed micelles,
was measured in lysates prepared from HEK 293 cells transiently transfected with vector (open circles) or mSphK1 (¢lled squares). Data are
meansTS.D. of triplicate determinations. Similar results were obtained in three independent experiments. Data were ¢t by non-linear regression
to the Michaelis^Menten equation with Sigma Plot (R2 = 0.99). The apparent Km values for D-erythro-sphingosine and FTY720 were 7T 1 and
11T 1 WM, respectively. Vmax values for D-erythro-sphingosine and FTY720 were 3850T 170 and 29T 1 pmol/min/mg, respectively. C: TLC
analysis of phosphorylated sphingosine and FTY720. The indicated concentrations of sphingosine and FTY720 were phosphorylated by lysates
from HEK 293 cells transfected with vector, mSphK1, or mSphK2. Phosphorylated products were extracted and separated by TLC on silica
gel G60 plates and radioactive spots were visualized by a phosphoimager.
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greater, lysates from SphK2-transfected cells more e¡ectively
phosphorylated FTY720 (Figs. 2C and 3). It should be noted
that phosphorylation of FTY720 by vector-transfected cells
was below detection limits, suggesting that high levels of
SphK2 must be present to signi¢cantly phosphorylate
FTY720. As with SphK1, saturation kinetics were also ob-
served with both FTY720 (Fig. 3B) and sphingosine as sub-
strates for SphK2 (Fig. 3A). While the apparent Km values for
both substrates were similar, SphK2 had much higher activity
with FTY720 as substrate than SphK1 and phosphorylated it
at 15% of the rate of phosphorylation of its natural substrate.
3.4. FTY720 inhibits phosphorylation of sphingosine
FTY720 is a substrate for both SphK1 and SphK2 and thus
might inhibit S1P formation by competing with sphingosine.
Because S1P and phosphorylated FTY720 cannot be sepa-
rated by TLC (Fig. 2C), the e¡ect of FTY720 on inhibition
of sphingosine phosphorylation was examined using
[3H]sphingosine as substrate. [3H]S1P produced was measured
by a di¡erential solvent extraction procedure by which S1P
partitions into the aqueous phase at alkaline pH with high
recovery while sphingosine remains in the organic phase
(Fig. 4A). When SphK1 activity was measured in the presence
of Triton X-100, FTY720 did not inhibit phosphorylation of
[3H]sphingosine (Fig. 4B). However, when both were pre-
sented as a complex with BSA, high concentrations of
FTY720 reduced [3H]S1P formation (Fig. 4B). It is not clear
why FTY720 only inhibits phosphorylation of sphingosine in
the absence of Triton X-100 but it is possible that the mixed
micelles might enhance the presentation of sphingosine to the
enzyme. FTY720 also inhibited [3H]sphingosine phosphoryla-
tion catalyzed by SphK2 (Fig. 4C). A concentration of 100
WM FTY720 inhibited phosphorylation of sphingosine medi-
ated by SphK2 by more than 80%.
Fig. 3. SphK2 phosphorylates FTY720. Phosphorylation of sphingosine (A) and FTY720 (B) added as BSA complexes was measured in the
presence of 200 mM KCl using lysates prepared from HEK 293 cells transiently transfected with vector (open circles) or mSphK2 (¢lled trian-
gles). Data are meansTS.D. of triplicate determinations. Similar results were obtained in three independent experiments. Data were ¢t by non-
linear regression to the Michaelis^Menten equation with Sigma Plot (R2 = 0.99). The apparent Km values for D-erythro-sphingosine and
FTY720 were 7T 1 and 13T 1 WM, respectively. Vmax values for D-erythro-sphingosine and FTY720 were 940T 50 and 170T 5 pmol/min/mg, re-
spectively.
C
Fig. 4. FTY720 inhibits phosphorylation of sphingosine by SphK1
and SphK2. A: Separation of [3H]S1P from [3H]sphingosine by dif-
ferential extraction. [3H]sphingosine phosphorylation was measured
in lysates from HEK 293 cells expressing SphK1 by the alkaline ex-
traction procedure. [3H]-labeled lipids in both aqueous and solvent
phases were separated by TLC and radioactivity determined with a
Bioscan AR-2000 scanner (Washington, DC, USA). B: E¡ect of
FTY720 on [3H]sphingosine phosphorylation catalyzed by SphK1.
SphK1 activity was measured with lysates from vector-transfected
(circles) or SphK1-transfected (squares) cells with 10 WM
[3H]sphingosine added as a complex with BSA (open squares) or in
Triton X-100 (¢lled squares) and the indicated concentrations of
FTY720. C: Dose-dependent inhibition of SphK2 by FTY720.
SphK activity in lysates from vector (open circles) or SphK2 (¢lled
triangles) transfectants was measured with 10 WM [3H]sphingosine
added as a BSA complex in the presence 200 mM KCl and increas-
ing concentrations of FTY720. Data are meansTS.D. of triplicate
determinations. Similar results were obtained in two independent ex-
periments.
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4. Conclusions
In this study, we have shown that FTY720 can be phos-
phorylated in vitro by both SphK1 and SphK2. Neither SphK
isozyme e⁄ciently utilizes FTY720 as substrate compared to
the natural sphingosine substrate, although SphK2 seems
more likely to be the relevant biological catalyst since it cata-
lyzes the phosphorylation of FTY720 at about 15% of the rate
of sphingosine phosphorylation and has similar a⁄nities for
both substrates, while SphK1 has less than 1% activity with
FTY720 compared to sphingosine. It remains to be deter-
mined how FTY720 is apparently so readily phosphorylated
in vivo and how the phosphorylated drug is transported out
of the cell. It is tempting to speculate that, in contrast to S1P,
phosphorylated FTY720 is ine⁄ciently dephosphorylated and
metabolized in vivo, thus remaining more available to activate
S1P receptors. Moreover, while SphK1 and more likely
SphK2 may indeed convert FTY720 to a bioactive S1P mi-
metic in vivo, it should be recognized that it is possible that
some FTY720 actions might result from decreased S1P for-
mation rather than direct e¡ects of phosphorylated FTY720.
Finally, it is still not clear how phosphorylated FTY720 is
recognized by S1P receptors which seem to have much more
exquisite requirements for ligand binding than the active sites
of SphKs for which FTY720 is a rather poor ¢tting substrate.
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